Gelonghui, May 17, 丨 Lepu Bio-B (02157.HK) announced that on May 17, 2024, the company (as issuer) entered into a placement agreement with the placement agent (CITIC Securities and HSBC). According to this, the placement agent conditionally agreed to act as the company's agent to place up to 51.17 million shares at the placement price of HK$4.58 per H share.

Placed shares accounted for about 3.19% and 3.08% of the company's total issued H shares and all existing issued share capital as of the date of this announcement; they also accounted for approximately 3.09% and 2.99% of the company's total issued H shares and all issued share capital, respectively, after the expansion of the placement shares issued in accordance with the placement matters.

Assuming that all of the placed shares are fully placed, the total amount of proceeds from the placement is expected to be approximately HK$234 million, while the total net proceeds from the placement are expected to be approximately HK$230 million. The company plans to use about 70% of the net proceeds from the placement process for R&D, clinical testing, registration and other work processes of the company's ADC candidate product; about 20% for clinical trials and other work processes of the company's oncolytic virus candidate CG0070; and about 10% to supplement the company's working capital and general corporate purposes.